Ryan Khouri, CEO of CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH), has increased his stake in the company by purchasing 23,346 shares. The transaction, which took place on November 25, 2024, was conducted at a price of $0.06 per share, amounting to a total investment of approximately $1,400. Following this acquisition, Khouri now directly owns 5,818,846 shares of the company. This move reflects Khouri's continued confidence in the company's prospects.
InvestingPro Insights
Ryan Khouri's recent purchase of CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) shares aligns with several interesting metrics from InvestingPro. The company's stock has seen a remarkable 132% price increase over the past six months, indicating strong momentum. This surge is particularly noteworthy given that CTTH is trading at a low Price / Book multiple, suggesting potential undervaluation despite the recent gains.
InvestingPro data shows that CTTH has a market capitalization of $3.12 million, placing it in the small-cap category. The stock's current price of $0.06 represents 50% of its 52-week high, which could indicate room for further growth if the company's fundamentals support it.
Two relevant InvestingPro Tips highlight that CTTH has a high shareholder yield and that its liquid assets exceed short-term obligations. These factors may have influenced Khouri's decision to increase his stake, as they suggest financial stability and potential value for shareholders.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide further insights into CTTH's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.